Publications
-
Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
Frontiers in oncology . 13: 1164949-1164949. Number of citations: 4
-
Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Cancers . 15(9): . Number of citations: 8
-
Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM.
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma
BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408. Number of citations: 7
-
Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J.
KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma
Biorxiv . : .
-
Cuadrado-Vilanova M, Burgeño-Sandoval V, Balaguer-Lluna L, Aschero MR, Castillo H, Liu, J, Pérez-Jaume S, Pascual-Pastó G, Gene-Olaciregui N, Gomez-Gonzalez S, Correa, G, Suñol M, Schaiquevich, P, Radvanyi, F, Lavarino C, Mora J, Català-Mora J, Chantada G and Carcaboso AM.
Follow-up of intraocular retinoblastoma through the quantitative analysis of conserved nuclear DNA sequences in aqueous humor from patients
JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 9(1): 32-43. Number of citations: 3
-
Cuadrado-Vilanova M, Liu J, Paco-Mercader S, Aschero MR, Burgeño-Sandoval V, Sirab N, Pascual-Pastó G, Correa G, Balaguer-Lluna L, Castillo H, Pérez-Jaume S, Muñoz-Aznar O, Roldan-Molina M, Suñol M, Schaiquevich P, Aerts I, Doz F, Cassoux N, Lubieniecki F, Benitez-Ribas D, Lavarino C, Mora J, Chantada G, Català-Mora J, Radvanyi F and Carcaboso AM.
Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients
JOURNAL OF PATHOLOGY . 257(3): 327-339. Number of citations: 7
-
García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.
MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
BMC Cancer . 22(1): 669-669. Number of citations: 10
-
Mesegue-Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Solà S.
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia
HEMATOLOGICAL ONCOLOGY . 39(5): 687-696. Number of citations: 7
-
Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S.
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
PEDIATRIC BLOOD & CANCER . 68(10): 29121. Number of citations: 21
-
Pérez JPM, Muchart-Lopez J, Santa-María López V, Suñol M, Salvador-Marcos N, Pérez-Jaume S, Cruz-Martínez O and Morales-La Madrid A.
Targeted therapy for pediatric low-grade glioma
CHILDS NERVOUS SYSTEM . 37(8): 2511-2520. Number of citations: 13